Group 1 - The core viewpoint of the news is that Yingpais (002899.SZ) has reported its Q3 2025 results, highlighting the significant institutional ownership and changes in shareholding among public funds [1][2] Group 2 - As of October 30, 2025, a total of 11 institutional investors disclosed holding shares in Yingpais, with a combined holding of 51.9842 million shares, accounting for 35.17% of the total share capital [1] - The top ten institutional investors collectively hold 35.10% of the shares, which is a decrease of 1.25 percentage points compared to the previous quarter [1] - In the public fund sector, four funds increased their holdings, accounting for a 0.36% increase, while two funds decreased their holdings, representing a 0.22% decrease [2] - One new public fund was disclosed during this period, while 75 funds were not disclosed compared to the previous quarter [2]

Group 1 - The fourth meeting of the Supervisory Board of Qingdao Impulse Health Technology Co., Ltd. was held on October 29, 2025, with all three supervisors present, complying with relevant laws and regulations [2][3][4] - The Supervisory Board unanimously approved the 2025 Q3 report, confirming that the report accurately reflects the company's actual situation without any false records or omissions [3][4] Group 2 - The company announced the second extraordinary general meeting of shareholders for 2025, scheduled for November 18, 2025, with both on-site and online voting options available [9][10][11] - The meeting will address proposals that have been approved by the Board of Directors, requiring a special resolution for certain items [17] Group 3 - The company plans to abolish the Supervisory Board and amend its Articles of Association, transferring the supervisory functions to the Audit Committee of the Board of Directors [33][34] - Key amendments to the Articles of Association include changing references from "General Meeting of Shareholders" to "Shareholders' Meeting," removing provisions related to the Supervisory Board, and lowering the shareholding threshold for shareholder proposals from 3% to 1% [34][35]

Group 1 - The company guarantees the authenticity, accuracy, and completeness of the information disclosed in its quarterly report, with no false records, misleading statements, or significant omissions [2][9][60] - The third-quarter financial report has not been audited [8][62] - The company has repurchased 1,256,700 shares, accounting for 0.85% of the total share capital as of the end of the reporting period [5] Group 2 - The fourth board meeting of the company was held on October 29, 2025, with all nine directors present, complying with relevant laws and regulations [10][11] - The board unanimously approved the third-quarter report, which reflects the company's actual situation accurately [11][62] - The company plans to hold the second extraordinary general meeting of shareholders on November 18, 2025, with both on-site and online voting options available [66][69]

Group 1 - The core point of the article is that Yingpais (SZ 002899) held its fifth board meeting of the fourth session on October 29, 2025, to review various documents including the proposal to amend the "Rules of Procedure for Board Meetings" [1] - For the first half of 2025, Yingpais reported that 99.2% of its revenue came from fitness equipment sales, while other sales accounted for 0.8% [1]

Core Viewpoint - Yingpais is a significant player in the domestic fitness equipment industry, focusing on the research, development, manufacturing, and sales of fitness equipment, with a well-established industrial chain and high brand recognition [1] Group 1: Business Performance - In Q3 2025, Yingpais reported revenue of 856 million yuan, ranking 5th among 17 companies in the industry, with the top competitor, Tianyuan Pet, generating 2.323 billion yuan [2] - The main business composition includes commercial products at 465 million yuan (80.92%), other products at 71.21 million yuan (12.39%), outdoor products at 3.713 million yuan (6.46%), and home products at 128.24 thousand yuan (0.22%) [2] - The net profit for the same period was 50.75 million yuan, placing the company 6th in the industry, with the leading company, Zhejiang Ziran, achieving a net profit of 183 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Yingpais had a debt-to-asset ratio of 38.51%, down from 43.16% year-on-year, which is higher than the industry average of 30.49% [3] - The gross profit margin for Q3 2025 was 26.56%, a decrease from 31.70% year-on-year, but still above the industry average of 23.75% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 24.69% to 14,800, while the average number of circulating A-shares held per shareholder increased by 32.78% to 10,000 [5] - Among the top ten circulating shareholders, Minsheng Jia Yin Continuous Growth Mixed A (007731) entered as the sixth-largest shareholder with 1.3563 million shares, while Huaxia Stable Growth Mixed (519029) increased its holdings by 116,000 shares [5] Group 4: Strategic Adjustments - The company is actively adjusting its marketing strategy by focusing on domestic niche markets and optimizing its overseas market layout to explore emerging markets [6] - In H1 2025, overseas sales revenue was 420 million yuan, a decrease of 5.68%, while domestic market revenue increased by 22.65% to 150 million yuan [6]

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the third quarter of 2025 compared to the same period last year [1] Financial Performance - In Q3 2025, the company achieved a revenue of 281 million yuan, representing a year-on-year decrease of 13.33% [1] - The net profit for Q3 2025 was 19.08 million yuan, down 47.23% year-on-year [1] - For the first three quarters of 2025, the company reported a total revenue of 856 million yuan, which is a decrease of 4.53% compared to the same period last year [1] - The net profit for the first three quarters of 2025 was 50.75 million yuan, reflecting a decline of 41.88% year-on-year [1]

青岛英派斯健康科技股份有限公司 董事会审计委员会工作细则 第一章 总则 第一条 为强化董事会决策能力，做到事前审计、专业审计，确保董事会对 经理层的有效监督，完善公司治理结构，根据《中华人民共和国公司法》（以下 简称《公司法》）、《上市公司治理准则》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等有关 规定及《青岛英派斯健康科技股份有限公司章程》（以下简称《公司章程》）要 求，公司特设立董事会审计委员会（以下简称"审计委员会"），并制定本工作 细则。 第二条 审计委员会是董事会下设的专门工作机构，对董事会负责，依照《公 司章程》和董事会授权履行职责。 第二章 人员组成 第三条 审计委员会成员由 3 名董事组成，均应当具备履行审计委员会工作 职责的专业知识和经验，其中独立董事 2 名，成员中至少有 1 名独立董事为会 计专业人士。审计委员会成员不得在公司担任高级管理人员。董事会成员中的 职工代表可以成为审计委员会成员。 第四条 审计委员会成员由董事长、1/2 以上独立董事或全体董事 1/3 以上 提名，并由董事会选举产生。 （一）审核公司的财务信息及其披 ...

青岛英派斯健康科技股份有限公司 募集资金管理办法 第一章 总则 第一条 为规范青岛英派斯健康科技股份有限公司（以下简称"公司"）募 集资金的存放、管理和使用，使其充分发挥效用，确保募集资金项目尽快达产达 效，最大限度地保障投资者的利益，根据《中华人民共和国公司法》（以下简称 《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、《上市公 司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《深圳证券交 易所股票上市规则》（以下简称《上市规则》）、《深圳证券交易所上市公司自 律监管指引第 1 号——主板上市公司规范运作》（以下简称《规范运作》）等有 关法律、法规、规范性文件及《青岛英派斯健康科技股份有限公司章程》（以下 简称《公司章程》）的规定和要求，结合公司的实际情况，制定本制度。 第二条 本制度所称募集资金是指公司通过发行股票或者其他具有股权性质 的证券，向投资者募集并用于特定用途的资金，不包括公司为实施股权激励计划 募集的资金。本制度所称超募资金，是指实际募集资金净额超过计划募集资金金 额的部分。 第三条 本制度是公司对募集资金存放、管理和使用的基本行为准则。如募 集资金投资项目通过公司 ...

青岛英派斯健康科技股份有限公司 董事会提名委员会工作细则 第一章 总则 第一条 为进一步规范公司董事和高级管理人员的选聘工作，优化董事会人 员组成，完善公司治理结构，根据《中华人民共和国公司法》《上市公司治理准 则》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等有关规定及《青岛英派斯健康科技股份有限 公司章程》（以下简称《公司章程》）要求，公司特设立董事会提名委员会（以下 简称"提名委员会"），并制定本工作细则。 第二条 董事会提名委员会是董事会下设的专门工作机构，对董事会负责， 依照《公司章程》和董事会授权履行职责。 第二章 人员组成 第三条 提名委员会成员由 3 名董事组成，其中独立董事 2 名。 第四条 提名委员会委员由董事长、1/2 以上独立董事或全体董事 1/3 以上 提名，并由董事会选举产生。 第五条 提名委员会设主任委员（召集人）1 名，由独立董事委员担任，负 责主持委员会工作。主任委员（召集人）由董事会选举产生。 提名委员会主任委员（召集人）负责召集和主持提名委员会会议，当委员会 主任委员（召集人）不能或无法履行职责时，由其指定 1 名 ...

青岛英派斯健康科技股份有限公司 内幕信息知情人登记制度 第一章 总则 第一条 为加强青岛英派斯健康科技股份有限公司（以下简称"公司"）内 幕信息管理，做好内幕信息保密工作，维护信息披露的公平原则，保护广大投资 者的合法权益，根据《中华人民共和国证券法》（以下简称《证券法》）《上市 公司信息披露管理办法》《上市公司监管指引第 5 号——上市公司内幕信息知情 人登记管理制度》《深圳证券交易所股票上市规则》等有关法律、法规和规范性 文件的规定，以及《青岛英派斯健康科技股份有限公司章程》《青岛英派斯健康 科技股份有限公司信息披露管理制度》的相关规定，特制定本制度。 第二条 公司董事会是公司内幕信息管理的管理机构。公司董事会应当按照 要求及时登记和报送内幕信息知情人档案，并保证内幕信息知情人档案真实、准 确和完整，董事长为主要责任人。董事会秘书负责办理公司内幕信息知情人的登 记入档和报送事宜。 证券事务部负责公司内幕信息的监控、信息披露以及内幕信息知情人登记的 具体工作。 1.公司的经营方针和经营范围的重大变化； 2.公司的重大投资行为，公司在 1 年内购买、出售重大资产超过公司资产总 额 30%，或者公司营业用主要资 ...